Quick Answer
Zenas BioPharma, Inc. reported Revenue (ASC 606) of $10.00 million for fiscal year 2025.
Zenas BioPharma, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $10.00M | +100.0% |
| 2024 | $5.00M | -90.0% |
| 2023 | $50.00M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | $10.00M | — | -80.0% |
| September 30, 2023 | $50.00M | — | — |
- Zenas BioPharma, Inc. showed an increase of +100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2023–2025 period, Zenas BioPharma, Inc.’s revenue (asc 606) has declined by 80.0% (from $50.00 million to $10.00 million).
- The most recent figure is from Zenas BioPharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: